19
Views
0
CrossRef citations to date
0
Altmetric
Feature Articles

Report on the EMA Workshop on clinical trial data and transparency

Pages 124-127 | Published online: 04 Mar 2014
 

Abstract

Access to patient data gathered in clinical trials is a highly controversial and complex issue that needs to balance three aspects: the public right to transparency regarding data used to approve new medicines, protection of the data privacy rights of patients involved in the studies, and commercial confidentiality concerns of the trial sponsors. In response to an increasing number of formal complaints about restrictive practices in publicising clinical data, the European Medicines Agency has started an initiative to enable access to patient-level study data. In November 2012, they organised a workshop to bring the stakeholders together to discuss and establish the way forward.

Additional information

Notes on contributors

Susan Bhatti

Susan Bhatti has worked in regulatory affairs for over 15 years and spent the past 6 years in clinical research, where she is involved in setting up and obtaining approval for clinical studies throughout Europe. Discussions with Ethics Committees in connection with data collected during clinical trials and the need for adequate data protection for patients are part of her daily work.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.